方盛制药: 方盛制药关于受让药品上市许可的进展公告

Group 1 - The company has acquired ownership of 20 registered pharmaceutical products from Kangyi Pharmaceutical Co., Ltd., including "Throat and Pharynx Clear Capsules" and "Zhebei Cough Syrup (Yellow Box)" in Hong Kong [2] - On June 3, 2025, the company signed an investment cooperation agreement to adjust the equity structure of its Hong Kong joint venture [2] - The Hong Kong joint venture, Hong Kong Fangsheng Pharmaceutical Co., Ltd., has completed registration in the Hong Kong Special Administrative Region, with the company contributing HKD 10 million for a 50% stake [2] Group 2 - To expedite the registration of the acquired pharmaceutical products in mainland China, the company signed a supplementary agreement on June 20, 2025, to adjust the transfer steps and payment terms [3][4] - The supplementary agreement does not constitute a major adjustment to the original transfer agreement and will not affect the acquisition of the pharmaceutical products [4]